Thank you.
You're now registered to receive updates. We'll keep you informed about new product information, support services, and educational programs as they become available.
go to home pageFor US Healthcare Professionals
You're now registered to receive updates. We'll keep you informed about new product information, support services, and educational programs as they become available.
go to home pageINBRIJA is indicated for intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD) treated with carbidopa/levodopa.
Please see the Full Prescribing Information.
Intermittent treatment of OFF episodes in patients with PD treated with CD/LD.
Contraindicated in patients taking or who have recently taken (within 2 weeks) nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine) due to hypertension risk. Discontinue use of nonselective MAO inhibitors at least 2 weeks prior to initiating INBRIJA.